OSE 2101

Drug Profile

OSE 2101

Alternative Names: EP-2101; IDM 2101; OSE-2101; Tedopi

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IDM Pharma
  • Developer OSE Immunotherapeutics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 07 Sep 2017 OSE Immunotherapeutics in collaboration with GERCOR plans a phase II trial for Pancreatic Cancer (Combination therapy, Late stage, metastatic disease)
  • 06 Sep 2017 OSE Immunotherapeutics and GERCOR agree to co-develop OSE 2101 France for Pancreatic cancer
  • 23 Jun 2017 OSE Immunotherapeutics temporarily suspends patient enrolment due to an emerging benefit/risk balance of the experimental treatment in the phase III Atalante 1 trial in Non small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top